We’re delighted to have worked with these dynamic and innovative companies during the first cohort of the Founders at the University of Cambridge Start Accelerator programme. Each of the chosen founding teams are taking IP-rich, deep tech ideas and turning them into companies that will help to solve global challenges from climate change to mental health and fixing the food chain.
Our Investor Demo Day Lookbook provides more information on the innovation and ingenuity these companies have created whilst reaching this new milestone of commercialising their life-long research.
AetoSense is on a mission to revolutionise control strategies around air quality with innovative ultrafine particle monitoring solutions. Their focus is on the critical impact of airborne particles on health and energy efficiency.
By inhibiting biofilms, BioTryp’s technology has the potential to revolutionise how we treat infection, providing a much-needed alternative to traditional antibiotic treatment.
Using proprietary marine microbes, BravelyCultured is replacing animal, tropical oil, and petroleum-based products, starting with eco-friendly biosurfactants to replace their petroleum-derived counterparts.
Molyon is producing the next-gen energy storage solution: the lithium-sulfur battery. Offering long-life batteries with twice the energy density of current lithium-ion batteries, at a fraction of the price due to more abundant materials.
Nanomation provides computer-vision software to the semiconductor industry, enabling clients to manufacture with advanced nanomaterials that are otherwise not usable within industry settings.
Protonera aims to realise the scalability of a novel plastic upcycling technology to transform waste plastics into green hydrogen and other value-added commodities.
Solving the biggest problem towards net-zero, fixing the UK electricity grid. VOLTQUANT offers the world’s first search engine for grid connections, empowering developers to connect seamlessly using a machine-learning-enabled platform.
William Oak Diagnostics is developing a point-of-care test for micronutrient deficiencies for maternal, infant and child health, bringing a better standard of health around the world.
Xterna’s technology identifies different cell types in the human body through engineered cell-specific binders. These binders could be used for diagnostics or coupled with therapeutics to aid drug delivery to specific cells.